The scientist’s investigation covers issues in Biochemistry, Enzyme, Genetics, Histone and Histone Demethylases. His Biochemistry study frequently draws connections to adjacent fields such as Stereochemistry. His Stereochemistry research includes themes of Mevalonate pathway and Farnesyl pyrophosphate.
In his study, Transcription, Transcriptional regulation and High-throughput screening is strongly linked to Methylation, which falls under the umbrella field of Histone. His Chromatin study incorporates themes from Hydroxylation, Subfamily, Chemoproteomics and Demethylase activity. The Short-chain dehydrogenase study combines topics in areas such as Sequence motif, Sequence alignment, NAD+ kinase and Protein family.
His primary areas of investigation include Biochemistry, Crystal structure, Stereochemistry, Crystallography and Enzyme. His study in Active site, Dehydrogenase, Reductase, Oxidoreductase and Histone is carried out as part of his Biochemistry studies. His Histone study combines topics in areas such as Chromatin and Cell biology.
In his study, Cancer research is inextricably linked to Epigenetics, which falls within the broad field of Chromatin. Udo Oppermann interconnects Biophysics and Catalysis in the investigation of issues within Crystal structure. His Enzyme study is mostly concerned with Short-chain dehydrogenase and Hydroxysteroid Dehydrogenases.
Udo Oppermann mostly deals with Cancer research, Epigenetics, Chromatin, Cell biology and Histone. His work deals with themes such as Endometriosis, Histone methyltransferase, Apoptosis, Amine oxidase and Mutant, which intersect with Cancer research. His Epigenetics study results in a more complete grasp of Biochemistry.
Biochemistry is represented through his Histone Demethylases and Drug discovery research. His Chromatin research also works with subjects such as
Chromatin, Biochemistry, Cell biology, Epigenetics and Histone are his primary areas of study. His study explores the link between Chromatin and topics such as Methylation that cross with problems in Histone code. His study in Drug discovery, Transfer RNA, HSD17B10, RNase P and Enzyme falls within the category of Biochemistry.
Udo Oppermann combines subjects such as Cell, Transcription factor, Glucocorticoid receptor and Bromodomain with his study of Cell biology. His research investigates the connection between Epigenetics and topics such as Demethylation that intersect with issues in Subfamily, IC50, Lysine and Molecular model. His studies deal with areas such as Molecular biology and Retinoblastoma protein as well as Histone.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Medium- and short-chain dehydrogenase/reductase gene and protein families: The SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes
K L Kavanagh;H Jornvall;Bengt Persson;U Oppermann.
Cellular and Molecular Life Sciences (2008)
Protein production and purification.
Nature Methods (2008)
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility
D M Evans;Spencer Cca.;J J Pointon;Z Su.
Nature Genetics (2011)
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Laurens Kruidenier;Chun-wa Chung;Zhongjun Cheng;John Liddle.
Short-chain dehydrogenases/reductases (SDR): the 2002 update.
Udo Oppermann;Charlotta Filling;Malin Hult;Naeem Shafqat.
Chemico-Biological Interactions (2003)
The relationship between the chemistry and biological activity of the bisphosphonates.
F H Ebetino;A M Hogan;S Sun;M K Tsoumpra.
Short‐chain dehydrogenases/reductases (SDRs)
Yvonne Kallberg;Udo Oppermann;Hans Jörnvall;Bengt Persson.
FEBS Journal (2002)
Critical Residues for Structure and Catalysis in Short-chain Dehydrogenases/Reductases
Charlotta Filling;Kurt D. Berndt;Kurt D. Berndt;Jordi Benach;Stefan Knapp.
Journal of Biological Chemistry (2002)
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
K. L. Kavanagh;K. Guo;James Edward Dunford;James Edward Dunford;James Edward Dunford;X. Wu.
Proceedings of the National Academy of Sciences of the United States of America (2006)
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
R. G. G. Russell;Z. Xia;J. E. Dunford;U. Oppermann.
Annals of the New York Academy of Sciences (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: